Business Wire

BYNDER

23.1.2024 13:45:26 CET | Business Wire | Press release

Share
AI innovation fuels record quarter for Bynder

Bynder, a global leader in enterprise digital asset management (DAM) has today released data highlighting the strategic importance of enterprise DAM and content for brands looking to grow amidst market uncertainty and economic headwinds.

  • Increased market demand highlighted by record number of new business logos and customer expansion in Q4 2023 as brands continue to see content as a strategic enabler
  • AI functionality drives demand and is included in nearly 50% of new business deals in Q4
  • Customers report time savings of 30-40% utilizing AI, and are 2x more likely to find the assets they need
  • Leading indicators show significant growth in enterprise DAM usage and integration as businesses look to improve efficiency and drive increased ROI from their investments in content.

The need to deliver customers an exceptional content experience is driving more brands to look for efficiency, speed to value and increased ROI in the creation, management and distribution of content. In this landscape an enterprise DAM platform becomes mission critical as organizations compete for share of wallet in a growing and increasingly crowded digital and retail marketplace.

Recent AI innovations have highlighted Bynder’s market leadership, and its host of AI and automation capabilities have led to continued growth in new business, customer adoption and platform usage. The latest of these innovations, AI Search Experience, enables identification of similar assets and text in images, as well as the ability to search using images and identify duplicate assets. These capabilities allow teams to find, reuse and deliver more relevant content, quicker and more effectively.

Brittany Chase, Project Specialist at Architecture and Planning firm, HFA, said, “AI Search Experience would save between 30% and 40% of time from not having to upload and tag assets that already exist in the DAM.” In addition, a US-based healthcare company attributed a minimum saving of 6 hours a week to the new AI functionality, enabling team members to focus on more strategic initiatives.

As organizations continue to use content as a strategic advantage, usage of enterprise DAM enables efficiency across the entire content lifecycle. Across 2023, Bynder saw a 38% year-on-year growth in the number of assets stored on their platform, and a 250% increase in delivery of assets from Bynder’s platform to websites. Over the holiday season Bynder saw an exponential uplift in assets created, stored and distributed as brands looked to deliver exceptional digital shopping experiences.

Bynder’s hosts the largest marketplace of out of the box integrations and in 2023 this grew 38%. In addition, Bynder reported a 176% increase in API calls to their platform showing the criticality of a connected ecosystem to improve content operations.

Bynder CEO Bob Hickey said, “As digital commerce continues to accelerate, brands need to provide a seamless content experience to their customers. Our continued year-on-year growth, culminating in a record Q4 in 2023, indicates that investment in an enterprise DAM platform is vital for those looking to deliver content experiences while gaining compelling value and ROI from their content operations and IT investments.

“We’re pleased to see that our ongoing innovation and market leadership in AI has further driven our growth in Q4, highlighting that AI has become a strategic tool for marketers looking to streamline content operations and improve customer experience.”

For more information on Bynder and its AI capabilities, please visit https://www.bynder.com/en/solutions/initiatives/ai-automation/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123344937/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye